lab notebook
Are peptide serums regulated? Cosmetic vs drug, decoded
Contents
Prepared by: Research Desk. Sources are linked for verification.
Lab note #0: the regulatory baseline. Before we write up any individual ingredient, here’s the frame every note on this site sits inside. Peptide serums sold in the U.S. are almost always cosmetics. That gives them a specific, and fairly light, regulatory status. Once you understand that status, product claims become much easier to read.
Observation 1: cosmetics don’t get FDA approval
The FDA does not approve cosmetic products before they go on sale, and it doesn’t approve most cosmetic ingredients either. Color additives are the main exception. The company that makes a product is legally responsible for making sure it is safe when used as labelled, and correctly labelled [1].
So a serum with palmitoyl pentapeptide-4 (sold as Matrixyl) or acetyl hexapeptide-8 (sold as Argireline) doesn’t have an “FDA approval”. If a label or ad says “FDA-approved peptides”, be suspicious. It’s either confused or misleading.
Observation 2: the claim decides the category
This is the core concept. U.S. law defines products by their intended use. Cosmetics are intended to cleanse, beautify, promote attractiveness or alter the appearance. Drugs are intended to diagnose, treat or prevent disease, or to affect the structure or any function of the body [1].
The FDA says intended use can be shown by claims on the label, in advertising, on websites and on social media, and even by consumer perception and the ingredients chosen [1]. In practice, the same jar of peptide cream can be a cosmetic or an unapproved drug depending on what the brand says about it.
(These are illustrations. The FDA judges real cases individually.)
That last example is a real issue for neurotransmitter-inhibitor peptides such as acetyl hexapeptide-8. Saying a topical product blocks muscle contraction is a claim about body function. A 2025 review also concluded that whether topically applied acetyl hexapeptide-8 can reach the neuromuscular junction at all “remains uncertain” [3].
Observation 3: MoCRA raised the floor in 2022
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) was the biggest change to U.S. cosmetic law in decades [2]. Its requirements are being phased in, but the main ones include:
Facility registration and product listing with the FDA;
Serious adverse event reporting by the “responsible person” named on the label;
Safety substantiation: companies must have adequate evidence that the product is safe;
Recordkeeping and labelling updates, including a domestic contact for adverse-event reports.
MoCRA still does not create pre-market approval. It does mean there is now a formal route to report a reaction, and that the company listed on the label is accountable.
Observation 4: “Clinically proven” isn’t a regulatory status
Many peptide brands cite “clinical studies”. In cosmetic science, these often mean small, company-run consumer tests, measured over a few weeks, sometimes without a placebo arm. Some ingredient studies are proper randomized, double-blind trials. For example, the 12-week split-face study of palmitoyl pentapeptide in 93 women [4] is a good model. Many marketing claims rest on much less. No agency checks “clinically proven” on a cosmetic before it appears on a box.
How to read a peptide serum claim (checklist)
Is the claim about appearance or about biology? “Looks” and “appearance” are cosmetic. “Repairs” and disease-related verbs are drug territory.
Is there a study, and is it published? Look for a journal name, sample size and a control group.
Who did the study? Ingredient suppliers fund many peptide trials. That’s not disqualifying, but it’s worth knowing.
Is the peptide named by its INCI name? “Peptide complex” tells you nothing.
Is there a U.S. contact for reactions? MoCRA requires one on the label.
What we don’t cover
Skin Peptide Labs covers topical cosmetics only. Injectable peptides and “research use only” vials sit outside cosmetic law, and the FDA has raised its own safety concerns about some of them. We don’t review or link to those products.
Reporting reactions
Cosmetic adverse events can be reported to the FDA and to the company listed on the label [2].
Status checked: 18 October 2026.
Not medical advice. This page reports published research and regulatory records for information only.